Michel Detheux
Gründer bei ITEOS THERAPEUTICS, INC.
Vermögen: 596 388 $ am 30.04.2024
Aktive Positionen von Michel Detheux
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ITEOS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2012 | - |
Vorstandsvorsitzender | 01.04.2012 | - | |
Gründer | 01.04.2012 | - | |
Präsident | 01.04.2012 | - | |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Direktor/Vorstandsmitglied | 01.01.2011 | - |
Vorstandsvorsitzender | 01.01.2011 | - | |
Gründer | 01.01.2011 | - | |
Präsident | - | - | |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Vorsitzender | 02.12.2021 | - |
Independent Dir/Board Member | 02.12.2021 | - | |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Vorsitzender | 12.04.2022 | - |
Karriereverlauf von Michel Detheux
Ehemalige bekannte Positionen von Michel Detheux
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Ludwig Cancer Research | Direktor/Vorstandsmitglied | - | - |
Iteos Belgium SA
Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - | |
Präsident | - | - | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Direktor/Vorstandsmitglied | 01.01.1995 | - |
Ausbildung von Michel Detheux
Université Catholique de Louvain | Doctorate Degree |
Statistik
International
Belgien | 5 |
Vereinigte Staaten | 3 |
Spanien | 2 |
Operativ
Director/Board Member | 5 |
Chief Executive Officer | 3 |
President | 3 |
Sektoral
Health Technology | 7 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ITEOS THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Health Technology |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Health Technology |
Iteos Belgium SA
Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium. | Health Technology |
Ludwig Cancer Research |
- Börse
- Insiders
- Michel Detheux
- Erfahrung